Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention
View/ Open
Author
Campo, Gianluca
Pavasini, Rita
Morciano, Giampaolo
Lincoff, Michael A.
C. Gibson, Michael
Kitakaze, Masafumi
Lonborg, Jacob
Ahluwalia, Amrita
Ishii, Hideki
Frenneaux, Michael
Ovize, Michel
Galvani, Marcello
Atar, Dan
Ibanez, Borja
Cerisano, Giampaolo
Biscaglia, Simone
Neil, Brandon J.
Asakura, Masanori
Engstrom, Thomas
Jones, Daniel A.
Dawson, Dana
Ferrari, Roberto
Pinton, Paolo
Ottani, Filippo
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1016/j.dib.2017.07.033Metadata
Show full item recordCitation
Campo, G., R. Pavasini, G. Morciano, M. A. Lincoff, M. C. Gibson, M. Kitakaze, J. Lonborg, et al. 2017. “Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention.” Data in Brief 14 (1): 197-205. doi:10.1016/j.dib.2017.07.033. http://dx.doi.org/10.1016/j.dib.2017.07.033.Abstract
Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3], [4], [5], [9], [10], [11], excluding a trial on metoprolol [12] and comparing trial with follow-up length <12 months versus those with longer follow-up [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. This article describes data related article titled “Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials” [17].Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537426/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375165
Collections
- HMS Scholarly Articles [17921]
Contact administrator regarding this item (to report mistakes or request changes)